Month: August 2021

DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”), which also constitutes a scheme circular under Irish law, is being sent as of July 30, 2021 to Strongbridge shareholders. As previously announced on May 24, 2021, Xeris Pharmaceuticals, Inc. (“Xeris”) and Strongbridge entered into a definitive transaction agreement pursuant to which Xeris will acquire Strongbridge in a stock and CVR...

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”). This second tranche was made available in connection with the Company’s successful positive initial results from...

Total GAAP revenue increased 43.0% year-over-year to $59.4 millionAnnual recurring revenue increased 42.4% year-over-year to $240.6 millionTotal number of customers reached over 41,000Cash flow from operations was $14.1 million and free cash flow was $12.8 millionTAMPA BAY, Fla., Aug. 02, 2021 (GLOBE NEWSWIRE) —  KnowBe4, Inc. (NASDAQ: KNBE), provider of the leading security awareness training and simulated phishing platform, today reported results for the second quarter ended June 30, 2021. “Our second quarter results exceeded our expectations across the board with record annual recurring revenue (ARR) of $241 million and total customers of over 41,000,” said Stu Sjouwerman, founder and chief executive officer of KnowBe4. “We are excited about the extremely positive response to the release of our newest product, Compliance...

Proceeds will fund continued development of IMVT-1401 in multiple indicationsNEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has received a $200 million strategic investment from Roivant Sciences. Immunovant intends to use the proceeds from this investment to advance the development of IMVT-1401 in multiple indications. Roivant has purchased 17,021,276 shares of Immunovant’s common stock at a price of $11.75 per share, which purchase has been approved by a special committee of Immunovant directors not affiliated with Roivant. This represents approximately a 15% premium to Immunovant’s 20 trading day volume weighted average price. After giving effect to the investment,...

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the first patient has been dosed in the Phase 2 trial of ZN-c3, the Company’s oral WEE1 inhibitor product candidate, in adult women with recurrent or persistent uterine serous carcinoma (USC). Following an end-of-Phase 1 meeting, the U.S. Food and Drug Administration agreed in principle that ZN-c3 has the potential for an accelerated approval pathway based on the Phase 2 global study design in USC. “This trial, with its potential accelerated approval pathway, underscores our potential ability to efficiently develop and advance promising therapeutic...

Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Declineof SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo Company Is Planning to Provide Continued Access to Patients Who Complete COURAGE-ALS and Patients Who Previously Participated in Cytokinetics Sponsored ALS Trials SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), a Phase 3 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), is open to enrollment. Reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program, slows the rate of calcium release from the...

Results for the Second Quarter of 2021:Net income attributable to the company of $9.7 million, or $0.20 per diluted share inclusive of a $3.8 million loss related to the sale of certain assets and a $9.5 million charge related to a private exchange of convertible notes Adjusted EBITDA of $54.8 million, exclusive of a $3.8 million loss related to the sale of certain assets Consolidated crush margin of $0.37 per gallon Strong liquidity position, with cash, cash equivalents and restricted cash of $615.4 million and $294.2 million available under committed credit facilitiesOMAHA, Neb., Aug. 02, 2021 (GLOBE NEWSWIRE) — Green Plains Inc. (NASDAQ:GPRE) today announced financial results for the second quarter of 2021. Net income attributable to the company was $9.7 million, or $0.20 per diluted share inclusive of a loss related to...

Results show that every six-week natalizumab IV administration provides a high level of efficacy in controlling MS disease activity in patients who switched from the approved every four-week dosing regimen Data from the first prospective, randomized, controlled study of an extended dosing schedule for natalizumab offer valuable insights and build on positive real-world effectiveness findings1,2,3 Updated analyses from the TOUCH® Prescribing Program indicate an average six-week dosing schedule is associated with an 88 percent reduction in the probability of developing PML4CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced results from the two-year prospective, randomized, interventional, controlled, open-label Phase 3b NOVA study (NCT03689972). NOVA was designed to estimate a potential...

FREMONT, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX, ENVXW), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today announced that the management team will present at the Oppenheimer 24th Annual Technology, Internet & Communications Conference on Wednesday, August 11, 2021 at 4:35 PM Eastern Time. You can access the webcast of the presentation from the News and Events section of Enovix’s website at https://ir.enovix.com. About Enovix Enovix is the leader in advanced silicon-anode lithium-ion battery development and production. The company’s proprietary 3D cell architecture increases energy density and maintains high cycle life. Enovix is building an advanced silicon-anode lithium-ion battery production facility in the U.S. for...

WASHINGTON, Aug. 02, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Global Arbitration Review (“GAR”) has recognized the Company and its Compass Lexecon subsidiary as top expert witness firms in its annual GAR 100 Expert Witness Firms’ Power Index. FTI Consulting ranked first overall, and Compass Lexecon ranked second. FTI Consulting and Compass Lexecon had a combined 23 Thought Leaders, experts who placed in the top 2% of Who’s Who Legal research. The next closest firm had six Thought Leaders. According to GAR’s analysis, FTI Consulting had 223 experts attend hearings between August 2018 and August 2020, almost three times the next firm. FTI Consulting had the most construction-related arbitrations of any firm, with 88. Compass Lexecon led all firms in investor-state hearings, with 39. In a new table...